Eli Lilly's Omvoh Boosts Control Over Ulcerative Colitis

Eli Lilly and Company has today reported that Omvoh (mirikizumab mrkz) treatment, in patients with moderately to severely active Ulcerative Colitis (UC), showed early and sustained improvements in bowel urgency severity, frequency, and stool deferral time.

These findings are based on the Phase 3b LUCENT URGE study to be presented on October 24-29 on the American College of Gastroenterology Annual Scientific Meeting in Phoenix, Arizona.

This trial, LUCENT URGE, is a first of its kind, as an inflammatory bowel disease trial that has been conducted to examine bowel urgency on three dimensions; severity, frequency, and stool deferral time.

Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation

At Week 12, respondents using Omvoh had a 55 per cent decrease in the daily bowel urgency events; at Week 28, the severity of urgency decreased over 50 per cent. Notably, by Week 28, nearly one-third of patients were able to delay going to the restroom for at least 15 minutes after feeling the urge—up from just 4 % at baseline.

Dr. David Rubin of the University of Chicago Medicine commented that for many people living with UC, the sudden, unpredictable need to find a restroom is highly disruptive, and these results reinforce that Omvoh can help patients reclaim control over a symptom long affecting quality of life.

Mark Genovese, Senior Vice President of Lilly Immunology Development, said “Lilly continues to advance innovative science to better understand and treat bowel urgency, recognizing that comprehensive management of ulcerative colitis must address the real-world challenges patients face every day,” said Mark Genovese, M.D., Senior Vice President of Lilly Immunology Development.

Overall, the LUCENT-URGE findings position Omvoh as a compelling option in UC treatment not only for remission but also for tackling one of the most disruptive symptoms: bowel urgency.